

The first China Commercial Insurance Innovative Drug List (CIIDL) for 2026



How will the CIIDL transform pricing and access for innovative care in China?

1 What is the Commercial Insurance Innovative Drug List (CIIDL)?


CIIDL objectives

- The CIIDL is a government-led formulary which recommends high value, high-cost innovative drugs for commercial insurance, with the aim of supplementing the NRDL, which provides more basic coverage
- The NHSA engages clinical and negotiation experts to establish an age list of innovative drugs, with the expectation that commercial insurance, such as City Commercial Insurance, will cover and provide funding for these recommended drugs

CIIDL timelines

- The concept of the CIIDL was first discussed in Jan 2025 by the NHSA, the negotiation initiated in Oct/Nov 2025 in parallel with NRDL negotiation
- The list was published on 7 Dec 2025, with implementation on 1 Jan 2026

2 What is the outcome of the first CIIDL negotiation?



- Out of the 19 drugs, **14 are in oncology** (of which 5 are domestic CAR-T therapies), **3 are in rare diseases**, and **2 are in neurology** (Alzheimer's disease)
- **7 out of 18** manufacturers of the included drugs are **foreign** (~40%)

3 What are the potential benefits of CIIDL inclusion?

Lower price cuts



CIIDL included drugs are exposed to **lower price cuts** vs. NRDL, press sources suggest ~**15-50%** decrease (vs. 60%+ for NRDL in recent years)



CIIDL drugs are also not targeted by **volume-based procurement reviews**, meaning that they may face lower price erosion in the future

Faster hospital adoption



Inpatient CIIDL drugs can be billed **outside of standard DRGs**; they are less limited by hospital budget constraints



CIIDL drugs are also not counted towards **Basic Medical Insurance patient co-pay thresholds**, lowering barriers to prescribing high-cost therapies

4 What is needed to drive successful implementation of the CIIDL?

Commercial insurance

Active inclusion of suggested drugs and designing **innovative payment models** to allow sustainable coverage

Government

Dedicated budget to co-fund drugs with commercial insurance and policies to **encourage commercial insurance uptake**



Manufacturer

Education for patients on CIIDL drugs and disease areas, and the development of **patient support programs** to further reduce co-pay and improve access

Hospital

Improved HCP familiarity with CIIDL drugs and **reimbursement pathways**, and more **cost-effective administration protocols**

NRDL = National Reimbursement Drugs List

NHSA = National Healthcare Security Administration

CAR-T = Chimeric Antigen Receptor T-cell

HCP = Healthcare Professional

Contacts

Bhaves Patel, Principal
+44 1223 783909 | bpatel@crai.com

Harvey Feng, Associate
+44 1223 783915 | wfeng@crai.com

CRA Charles River
Associates